Kalaris Therapeutics Inc [KLRS] stock is trading at $4.66, up 1.97%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KLRS shares have gain 51.30% over the last week, with a monthly amount glided 82.75%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kalaris Therapeutics Inc [NASDAQ: KLRS] stock has seen the most recent analyst activity on September 03, 2025, when Raymond James initiated its Strong Buy rating and assigned the stock a price target of $23. On May 07, 2025, Leerink Partners initiated with a Outperform rating and assigned a price target of $20 on the stock. William Blair started tracking the stock assigning a Outperform rating.
Kalaris Therapeutics Inc [KLRS] stock has fluctuated between $2.14 and $24.15 over the past year. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Kalaris Therapeutics Inc [NASDAQ: KLRS] shares were valued at $4.66 at the most recent close of the market. An investor can expect a potential drop of -35.62% based on the average KLRS price forecast.
Analyzing the KLRS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -7.09 and Total Capital is -0.76.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.21 points at the first support level, and at 3.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.06, and for the 2nd resistance point, it is at 5.45.
Ratios To Look Out For
For context, Kalaris Therapeutics Inc’s Current Ratio is 11.98. As well, the Quick Ratio is 11.98, while the Cash Ratio is 11.56.
Transactions by insiders
Recent insider trading involved Hagen Brett R, Chief Accounting Officer, that happened on Mar 26 ’25 when 907.0 shares were sold.
